Healthcare stocks have had a strong run in 2026, but that strength is starting to invite its own risk. Heavy call buying has followed sharp rallies in GE HealthCare Technologies (NASDAQ: GEHC) and Medtronic (NYSE: MDT), pushing put-call ratios to levels that some options strategists now view as sell signals for both names.
GE HealthCare climbed more than 12% over a recent three-month stretch before crowded optimism showed up in the options data. Medtronic has soared roughly 26% since late May, triggering a similar contrarian warning. Both moves came alongside genuinely strong earnings reports, which is exactly what makes the setup tricky.
Strong fundamentals and crowded positioning can coexist. When too many investors chase the same trade at once, even good news struggles to push a stock higher. The next disappointment, however small, can trigger an outsized reaction. For investors watching the broader healthcare rally, GEHC and MDT are worth studying as a warning sign, not just two individual trade ideas.
What The Options Chains Are Signaling
Options positioning offers a read on sentiment that price alone doesn’t capture. When call buying dramatically outpaces put buying, it usually means traders are leaning heavily toward more upside. That’s bullish until it isn’t.
In GEHC’s options chain, near-term contracts show meaningful open interest building on the call side even as the stock has slid from its August highs near $77 down toward $67. That divergence, calls still active while price weakens, is a classic sign that positioning hasn’t caught up with reality yet.
Medtronic’s chain tells a related story. Volume and open interest cluster around strikes just above and below the current $92 level, with call-heavy activity following the stock’s climb off its May lows. Both patterns point to the same conclusion: traders have been betting on continuation, not correction.
That’s the setup options strategists watch for. Crowded call positioning after a big run doesn’t guarantee a pullback. But it does mean the risk-reward has shifted. New money coming into these names now is paying up for optimism that’s already been priced in once.
GEHC Earnings: Strong Quarter, Weaker Reaction
GE HealthCare’s second-quarter results, released in late July, were genuinely solid. Revenue reached $5.3 billion, up 5.7% year-over-year, with organic growth of 3.5%. Adjusted earnings per share came in at $1.13, up 6.6%.
The company’s growth engines performed well. Advanced Imaging Solutions grew 7.9%, and Pharmaceutical Diagnostics jumped 15.6%. Orders growth hit 11.1%, the strongest pace since the company’s 2023 spinoff from GE. Backlog climbed to a record $23.9 billion, with a book-to-bill ratio of 1.15 times.
Management reaffirmed full-year guidance: organic revenue growth of 3% to 4%, adjusted EBIT margin of 15.4% to 15.7%, and adjusted EPS between $4.80 and $5.00. Shares jumped 12% the morning when the results were released.
But that pop didn’t hold. Patient Care Solutions revenue fell 13.3%, and the stock has since drifted well below its 200-day moving average. The underlying business is executing. The stock, weighed down by crowded call positioning built during the rally, hasn’t been able to hold its gains. That combination, strong numbers and fading price action, is often where contrarian sell signals start to matter.
MDT Earnings: A Blowout Quarter, But Watch The Caveats
Medtronic’s first-quarter fiscal 2027 results, released September 1, were even stronger on the surface. Revenue hit $9.8 billion, up 13.7%; both figures were in line with analysts’ expectations and reflected organic growth. Non-GAAP EPS reached $1.45, up 15.1% year-over-year.
Cardiovascular led the way, growing 19.5% as reported. Cardiac Ablation Solutions surged 88% worldwide, gaining nine points of U.S. market share. Diabetes revenue grew 16.9%, and Medical Surgical and Neuroscience both posted double-digit or near double-digit gains.
Management raised full-year guidance twice over: organic revenue growth guidance was raised to 7.25%-7.75%, and non-GAAP EPS guidance rose to $5.94-$6.00. Shares jumped roughly 2.5% in premarket trading on the news.
Here’s the caveat worth flagging for readers. Medtronic’s quarter included an extra fiscal week, worth an estimated $570 million, or about 670 basis points, of that organic growth figure. Strip that out, and the underlying growth was closer to 7%, still the company’s best pace in nearly eight years, but not quite as dramatic as the headline number suggests.
That distinction matters for the crowding thesis. Options traders piling into calls after a 26% run may be reacting to the headline growth rate rather than the adjusted one. When the calendar boost rolls off next quarter, comparisons get tougher. That’s exactly the kind of gap between perception and fundamentals that can catch crowded positioning off guard.
The Takeaway For Investors
GEHC and MDT both delivered real, defensible earnings beats. Neither stock’s fundamental story is in question right now. What’s changed is the crowd around them.
When call buying accelerates faster than a stock can justify, the trade becomes as much about positioning as it is about performance. That’s the risk sitting underneath healthcare’s hot streak. A sector can be fundamentally sound and still leave short-term investors exposed if sentiment runs too far ahead of the numbers.
For investors holding GEHC or MDT, the message isn’t to panic. It’s to recognize that some of the recent upside may already be priced in through options markets. Watching how put-call ratios normalize after this stretch could offer an early read on whether the broader healthcare rally still has room to run or needs to cool off first.
